Bristol-myers Squibb Compnay

Lopa V Desai

David Kenneth Leahy

Yu Fan

Thorsten Rosner

Sunil S Patel

Collin Chan

Masano Sugiyama

Benjamin Cohen

Guanglin Luo

Ronald L Hanson

Martin D Eastgate

Yi Xiao

Qi Gao

Gregory L Beutner

Michael Shawn Lawler

Bin Zheng

Nicolas Cuniere

Christopher S Regens

Neil A Strotman

Paul C Lobben

Carolyn S Wei

Keming Zhu

Michael Bryan Hay

Monica Fitzgerald

The disclosure generally relates to a process for the preparation of compounds of formula I, including synthetic intermediates which are useful in the process. 

Process for the preparation of cycloheptapyridine CGRP receptor antagonists

The invention relates to an improved process for synthesizing N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (I) Compound (I) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis. 

Process for the preparation of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide

The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD). 

CGRP receptor antagonists

Growing community of inventors

Chesterfield, NJ, United States of America

Lopa V Desai